The Latest

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    This week in charts: What’s driving biotech’s recent pullback?

    The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks of late and the frenetic pace of startup buyouts this year. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

    Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Autoimmune drug developer Bambusa Therapeutics joined Aspen in revealing IPO plans on Friday. Two other biotechs could price offerings this week.

    Updated 9 hours ago
  • A person in a blue pinstripe suit looks straight ahead.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    HHS launches new plan to strengthen vaccine injury research, reporting

    Spearheaded by vaccine skeptic Robert F. Kennedy Jr., the initiative will involve a new NIH clinic, an updated monitoring system and reimbursements for doctors who report suspected side effects.

    Updated Oct. 9, 2026
    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

    The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.

  • The building features a modern glass façade with the Nasdaq logo prominently displayed. Surrounding the structure are other commercial buildings and digital billboards, which are characteristic of the vibrant Times Square environment.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    IPO window

    TRex Bio prices $117M IPO to support immune drug work

    Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris
    Image attribution tooltip

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx falls as Sjögren’s setback offsets celiac drug progress

    A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart. 

  • A neurodegenerative disease concept illustration
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    A Takeda spinout builds case for its Parkinson’s drug

    Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

  • Banners marking the 2025 American Society of Clinical Oncology's annual meeting hang from the ceiling of a conference hall.
    Image attribution tooltip
    Ned Pagliarulo/BioPharma Dive
    Image attribution tooltip

    The top biopharma conferences in 2027

    Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

  • An illustration of CRISPR-cas9 gene editing
    Image attribution tooltip
    del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
    Image attribution tooltip
    Gene editing

    Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climate

    Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives” instead.

  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Trump administration

    5 FDA decisions to watch in the fourth quarter of 2026

    The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

    FDA
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

    A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.

  • A set of three EU flags blows in the wind in front of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds

    The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.

  • Photomicrograph of a diffuse large B-cell lymphoma (DLBCL) a type of non-Hodgkin lymphoma.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

    The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

  • An illustration of a cancerous tumor inside the lungs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ArriVent collapses on disappointing lung cancer data

    More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share. 

  • Illustrated streptococcus pneumoniae bacteria are colored yellow against a dark background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data

    The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3 trials.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

    The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.

  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Shionogi pays $2B to acquire a rare disease startup

    The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.

  • A scientist in white jacket operates radiopharmaceutical manufacturing equipment.
    Image attribution tooltip
    Courtesy of GE HealthCare
    Image attribution tooltip

    GE HealthCare to acquire Sofie Biosciences for $945M

    The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.

  • A sign spelling Novartis hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

    In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.

  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking

    The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

  • Digital tablet displaying “AI AGENTS” with connected icons representing data, cloud computing and automated tools.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    An AI agent made a tiny drug R&D mistake. Then it kept going.

    The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is accelerating. Track the deals that are happening here.

    Viatris’ purchase of Pacira Biosciences is the first acquisition of a publicly traded biopharmaceutical company in more than two months, according to BioPharma Dive data.

    Updated Oct. 8, 2026
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    3 takeaways from a European obesity scientific meeting

    Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.